Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1999)
Metodica di ringiovanimento del viso mediante infiltrazioni di biomateriali a base di collagene purificato e acido ialuronico cross - linked ( hylan B gel )
Larsen Larsen, Kling Kling, Balazs Balazs, Leshchiner Leshchiner (1990)
Hylan gel for soft tissue augmentation. Society for Biomaterials 16th Annual Meeting (Abstract), May 20–23, Charleston, SCTrans. Soc. Biomaterials, XIII
The Role of Hyaluronan in Inflammation Control (Abstract)
Intercellular matrix therapy: hylans expand the possibilities
(1993)
Hyaluronan, hylans and their medical applications
W. Richter (1974)
Non-immunogenicity of purified hyaluronic acid preparations tested by passive cutaneous anaphylaxis.International archives of allergy and applied immunology, 47 2
A. Richter, E. Ryde, E. Zetterström (1979)
Non-immunogenicity of a purified sodium hyaluronate preparation in man.International archives of allergy and applied immunology, 59 1
Management of adhesions and tissue augmentation with viscoelastics - hyaluronan derivatives
N. Larsen, E. Leshchiner, E. Balazs, C. Belmonte (1995)
Biocompatibility of Hylan Polymers in Various Tissue CompartmentsMRS Proceedings, 394
M. Olenius (1998)
The First Clinical Study Using a New Biodegradable Implant for the Treatment of Lips, Wrinkles, and FoldsAesthetic Plastic Surgery, 22
(1995)
Handbook of Biomaterials and Applications, New York
E. Balazs (1991)
Medical Applications of Hyaluronan and its Derivatives
(1989)
Local intravascular drug delivery via percutaneous embolization with hylan gel
Larsen Larsen, Leshchiner Leshchiner, Parent Parent, Endrickson‐Aho Endrickson‐Aho, Balazs Balazs (1989)
Local intravascular drug delivery via percutaneous embolization with hylan gel. Society for Biomaterials 15th Annual. Meeting (Abstract), April 28‐ May 2, Lake Buena Vista, FLTrans. Biomaterials, XII
P. Smith, R. Krohn, G. Hermanson, A. Mallia, F. Gartner, M. Provenzano, E. Fujimoto, N. Goeke, B. Olson, D. Klenk (1985)
Measurement of protein using bicinchoninic acid.Analytical biochemistry, 150 1
E. Balazs, P. Bland, J. Denlinger, A. Goldman, N. Larsen, E. Leshchiner, A. Leshchiner, B. Morales (1991)
Matrix engineering.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2 1
(1996)
Annual Meeting of the Svenska Bindvavsklubben to honor Professor Toward Laurent. Medevi, Sweden: BXR 9008
N. Larsen, E. Leshchiner, E. Parent, E. Balazs (1991)
Hylan and Hylan Derivatives in Drug Delivery
N. Larsen, E. Leshchiner, C. Pollak, E. Balazs (1995)
Evaluation of Hylan B (Hylan Gel) as Soft Tissue Dermal ImplantsMRS Proceedings, 394
N. Larsen, E. Balazs (1991)
Drug delivery systems using hyaluronan and its derivativesAdvanced Drug Delivery Reviews, 7
L. Drake, S. Dinehart, E. Farmer, R. Goltz, G. Graham, M. Hordinsky, C. Lewis, D. Pariser, D. Whitaker, B. Butler, B. Lowery (1996)
Guidelines of care for soft tissue augmentation: collagen implants. American Academy of Dermatology.Journal of the American Academy of Dermatology, 34 4
N. Larsen, E. Leshchiner, E. Parent, J. Hendrikson-Aho, E. Balazs, S. Hilal (1991)
Hylan gel composition for percutaneous embolization.Journal of biomedical materials research, 25 6
H. Fillit, M. Mccarty, M. Blake (1986)
Induction of antibodies to hyaluronic acid by immunization of rabbits with encapsulated streptococciThe Journal of Experimental Medicine, 164
Larsen Larsen, Parent Parent, Balazs Balazs (1991)
Release of the antibiotic gentamicin from hylan vehicles. Society for Biomaterials (Abstract), 17th Annu. Meet., May 1–5, Scottsdale, AZTrans Soc Biomaterials, XIV
Endre Balazs, J. Denlinger (2007)
Clinical uses of hyaluronan.Ciba Foundation symposium, 143
(1991)
Release of the antibiotic gentamicin from hylan vehicles
N. Larsen, C. Pollak, Karen Reiner, E. Leshchiner, E. Balazs (1994)
Hylan Gel for Soft Tissue Augmentation
Smith Smith, Krohn Krohn, Aermanson Aermanson, Hallia Hallia, Gartner Gartner, Provenzano Provenzano, Fujimoto Fujimoto, Goeke Goeke, Olson Olson, Klenk Klenk (1985)
Measurement of protein using bieinchoninie acidAnnual Biochem, 150
W. Comper, T. Laurent (1978)
Physiological function of connective tissue polysaccharides.Physiological reviews, 58 1
N. Larsen, C. Pollak, Karen Reiner, E. Leshchiner, E. Balazs (1993)
Hylan gel biomaterial: dermal and immunologic compatibility.Journal of biomedical materials research, 27 9
Hyaluronic acid (HA) derivatives have been developed to try to enhance Theological properties of this molecule to make it suitable for various medical applications. The main dermatological application of HA derivatives is the augmentation of soft tissues, via injection into the dermis. HA derivatives are indicated for the correction of cutaneous contour deficiencies of the skin, particularly in cases of ageing or degenerative lesions or to increase lips. Two HA derivatives have been evaluated: Hylaform® Viscoelastic Gel (Hylan B), derived from rooster combs and subjected to cross‐linking, and Restylane®, produced through bacterial fermentation (streptococci) and stabilized, as declared by the producer. In both cases the purpose is to improve HA rheological characteristics and slow down its degradation once it is in contact with biological structures. Distribution of particle dimensions, pH, protein concentration and rheological properties have been investigated in order to evaluate their reliability as fillers for soft tissue augmentation. The results of the analyses showed that there are differences between Restylane® and Hylaform®. Especially as far as rheological characteristics are concerned, the results outline different structures of the products: Hylaform® behaves as a strong hydrogel, Restylane® as a weak hydrogel; theologically Hylaform® is clearly superior to Restylane®. Hylaform® contains a definitely minor quantity (about a quarter) of cross‐linked hyaluronic acid than Restylane®. Furthermore, although not declared by the manufacturer, Restylane® contains protein, resulting from bacterial fermentation or added to enable cross‐linking reaction; the quantity of proteins contained by Restylane® can be as much as four times the quantity contained by Hylaform®, for the same volume (1 ml). It is evident that Hylaform® offers higher safety margin than Restylane®. Furthermore, wide literature and 20 years of clinical experience on hyaluronan derived from rooster combs confirm the reliability of this derivative while we did not find evidence regarding about the safety of HA obtained from streptococcus.
Journal of the European Academy of Dermatology & Venereology – Wiley
Published: Nov 1, 1999
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.